Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of magnoflorine in preparation of bone regulation drug synergist and pharmaceutical composition containing magnoflorine

A technology of magnolia base and composition, which is applied in the direction of drug combination, active ingredient of heterocyclic compound, pharmaceutical formula, etc., can solve the problem of difficult medicinal effect, and achieve the effect of promoting differentiation and mineralization

Active Publication Date: 2021-07-16
JINAN UNIVERSITY
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the efficacy of these traditional Chinese medicine ingredients is often much lower than estrogen (100-1000 times lower than estrogen), and it is difficult to achieve medicinal effects through oral administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of magnoflorine in preparation of bone regulation drug synergist and pharmaceutical composition containing magnoflorine
  • Application of magnoflorine in preparation of bone regulation drug synergist and pharmaceutical composition containing magnoflorine
  • Application of magnoflorine in preparation of bone regulation drug synergist and pharmaceutical composition containing magnoflorine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Effect of magnolanine with different test concentrations on MC3T3-E1 cell differentiation and mineralization activity

[0052] 1. Drug configuration to be tested

[0053] The purity of magnoflorine (CAS: 6681-18-1), psoralen (CAS: 66-97-7) and sweroside (CAS: 14215-86-2) is greater than 98% , purchased from Shanghai Ronghe Pharmaceutical Technology Development Co., Ltd., the structural formula is as follows figure 1 shown. In order to avoid the influence of the solvent on the cells, in this study, the drug was dissolved and administered according to one-thousandth of the volume of the administration medium, so all the drugs in this study were prepared at a concentration of 1000% of the final concentration of the drug-containing medium before administration For example, in the example, 10nM 17β-estradiol is used as a positive drug, and the dosing process is to add 1 μL of 10 μM 17β-estradiol to 1 mL of differentiation induction medium and mix to obtain a fina...

Embodiment 2

[0071] Example 2 Effects of magnolanine on the differentiation and mineralization of MC3T3-E1 cells induced by psoralen or glycosides

[0072] 1. Preparation of drug to be tested

[0073] Refer to Sections 1.1 to 1.8 in Example 1.

[0074] 2. Experimental method

[0075] 2.1. Cell differentiation activity

[0076] For the effect of magnolialine on the differentiation and mineralization activity of MC3T3-E1 cells induced by psoralen or psoralen, the experiment refers to part 2.1 in Example 1. The difference is that the specific dosing is: take 0.5 mL of Add 0.5 μL of the following solutions to the bone differentiation induction medium: blank solvent (absolute ethanol), 10 μM positive drug 17β-estradiol, different sample solutions to be tested (10 μM psoralen, 10 μM glycoside, 10 μM magnolialine, composition MP, and composition MS) were co-cultured for 7 days, and the drug-containing induction culture medium was replaced every 2 to 3 days. Experiments were repeated at least ...

Embodiment 3

[0081] Example 3 The effect of the composition MPS of magnolialine, psoralen and glucoside on the differentiation and mineralization activity of MC3T3-E1 cells

[0082] 1. Preparation of drug to be tested

[0083] Refer to Sections 1.1 to 1.8 in Example 1.

[0084] 2. Experimental method

[0085] 2.1. Cell differentiation activity

[0086] The influence experiment of the composition MPS of magnolialine, psoralen and glucoside on the differentiation and mineralization activity of MC3T3-E1 cells refers to part 2.1 in Example 1, the difference is that the specific dosing is as follows: Add 0.5 μL of the following solutions to 0.5 mL of osteogenic differentiation induction medium: blank solvent (absolute ethanol), 10 μM positive drug 17β-estradiol, different sample solutions to be tested (10 μM magnolialine, 10 mM psoralen, 1 mM When drug glycosides, composition PS and composition MPS) were co-cultured for 7 days, the drug-containing induction culture medium was replaced every ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of magnoflorine in preparation of a bone regulation drug synergist and a pharmaceutical composition containing magnoflorine, and belongs to the technical field of biological medicines. The magnoflorine can be used for preparing the bone regulation drug synergist and can further be used for preparing a pharmaceutical composition with the effect of promoting osteoblast differentiation and mineralization. The pharmaceutical composition is prepared from one or two of psoralen and sweroside, and magnoflorine. The magnoflorine can be widely applied to the field of medicines, and can provide a new medicine source for the treatment of osteoporosis diseases.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of magnolanine in the preparation of synergists for bone-regulating drugs and a pharmaceutical composition containing magnolanine. Background technique [0002] Orthopedic disease is one of the common diseases characterized by bone lesions. Common orthopedic diseases include patellar fracture, osteoporosis, ulnar nerve injury, congenital coxa varus, replantation of severed finger, interphalangeal neuralgia, posterior lateral talus Nodal fracture, patella fracture, thumb reconstruction, congenital tibial defect, etc. [0003] Osteoporosis is a systemic and systemic metabolic disease characterized by decreased bone mass and damage to the fine structure of bone, leading to fractures. Current data shows that about 200 million people in the world suffer from osteoporosis, and its incidence rate ranks seventh among common diseases and frequently-occurrin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/473A61K31/37A61K31/7048A61P19/08A61P19/10A61P19/00A61P19/02
CPCA61K31/473A61K31/37A61K31/7048A61P19/08A61P19/10A61P19/00A61P19/02A61K2300/00
Inventor 戴毅唐曦阳吴清昌邱佐成肖辉辉黄文秀姚新生
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com